Anhui Fengyuan Pharmaceutical Co., Ltd.

Equities

000153

CNE0000014X5

Pharmaceuticals

End-of-day quote Shenzhen S.E. 23:00:00 30/05/2024 BST 5-day change 1st Jan Change
8.55 CNY +0.47% Intraday chart for Anhui Fengyuan Pharmaceutical Co., Ltd. -1.38% -8.75%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Anhui Fengyuan Pharmaceutical Co., Ltd. Announces 2023 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 07 June 2024 CI
Anhui Fengyuan Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2023 CI
Fengyuan Pharma Gets Nod to Register Two Dialysis Solutions MT
Anhui Fengyuan Pharmaceutical Co., Ltd. Proposes Final Cash Dividend (Tax Included) for 2023 CI
Anhui Fengyuan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Anhui Fengyuan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Anhui Fengyuan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Anhui Fengyuan Pharmaceutical Co., Ltd. canceled the acquisition of Anhui Tiger Biotech Co., Ltd. from Anhui Taige Biological Technology Co., Ltd. CI
Anhui Fengyuan Pharmaceutical Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on June 16, 2023 CI
Anhui Fengyuan Pharmaceutical Announces Cash Dividend for 2022 CI
Anhui Fengyuan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Anhui Fengyuan Pharmaceutical Co., Ltd. Announces Final Cash Dividend (Tax Included) for 2022 CI
Anhui Fengyuan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Anhui Fengyuan Pharmaceutical Co., Ltd. agreed to acquire Anhui Tiger Biotech Co., Ltd. from Anhui Taige Biological Technology Co., Ltd. CI
Anhui Fengyuan Pharmaceutical Co., Ltd. announced a financing transaction CI
Anhui Fengyuan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Anhui Fengyuan Pharmaceutical Co., Ltd. signed an equity transfer agreement to acquire Anhui Fengyuan Gelatin Co., Ltd. from BBCA Group Co., Ltd. for approximately CNY 308 million. CI
Anhui Fengyuan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Anhui Fengyuan Pharmaceutical Co., Ltd. Announces Management Appointments CI
Anhui Fengyuan Pharmaceutical Co., Ltd. Announces Cash Dividend for A Shares for the Year 2021, Payable on 05 July 2022 CI
Anhui Fengyuan Pharmaceutical Co., Ltd. Approves Cash Distribution for 2021 CI
Anhui Fengyuan Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2021 CI
Anhui Fengyuan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Anhui Fengyuan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Anhui Fengyuan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Chart Anhui Fengyuan Pharmaceutical Co., Ltd.
More charts
ANHUI FENGYUAN PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research and development, manufacture and distribution of biological medicines, chemical synthetic medicines and Chinese medicines. The Company's products mainly include antipyretic and analgesic, women and children, the nervous system, cardiovascular, urinary system, nutrition, antibiotics and active ingredient and other products. The Company is also engaged in the retailing and wholesale of drugs. The Company conducts its businesses mainly in domestic markets, with Anhui province as its main market.
More about the company
  1. Stock Market
  2. Equities
  3. 000153 Stock
  4. News Anhui Fengyuan Pharmaceutical Co., Ltd.
  5. Fengyuan Pharma Gets Nod to Register Two Dialysis Solutions